![Designing greener active pharmaceutical ingredients: Insights from pharmaceutical industry into drug discovery and development - ScienceDirect Designing greener active pharmaceutical ingredients: Insights from pharmaceutical industry into drug discovery and development - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0928098723002440-ga1.jpg)
Designing greener active pharmaceutical ingredients: Insights from pharmaceutical industry into drug discovery and development - ScienceDirect
![SAVE (Super-dose Anti-VEGF) Trial: 2.0 mg Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration: 1-Year Results | Ophthalmic Surgery, Lasers and Imaging Retina SAVE (Super-dose Anti-VEGF) Trial: 2.0 mg Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration: 1-Year Results | Ophthalmic Surgery, Lasers and Imaging Retina](https://journals.healio.com/cms/asset/75077ee3-36f4-4f62-82d3-f8da2ced001f/10.3928_23258160-20130313-04-table1.jpg)
SAVE (Super-dose Anti-VEGF) Trial: 2.0 mg Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration: 1-Year Results | Ophthalmic Surgery, Lasers and Imaging Retina
![Suspect and Nontarget Screening Reveal the Underestimated Risks of Antibiotic Transformation Products in Wastewater Treatment Plant Effluents | Environmental Science & Technology Suspect and Nontarget Screening Reveal the Underestimated Risks of Antibiotic Transformation Products in Wastewater Treatment Plant Effluents | Environmental Science & Technology](https://pubs.acs.org/cms/10.1021/acs.est.3c05008/asset/images/medium/es3c05008_0002.gif)